Vision in depressive disorder

World Journal of Biological Psychiatry

Volumn 10, Issue 4 PART 2, 2009, Pages 377-384

  Bubl, Emanuel ^a   Tebartz Van Elst, Ludger ^a   Gondan, Matthias ^b   Ebert, Dieter ^a   Greenlee, Mark W ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Contrast sensitivity; Depressive disorder; Dopamine; Schizophrenia

Indexed keywords

CONTRAST MEDIUM; DOPAMINE;

ADULT; AGE DISTRIBUTION; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DOPAMINERGIC NERVE CELL; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; NEUROTRANSMISSION; REACTION TIME; SENSITIVITY ANALYSIS; VISION; ATTENTION; BIPOLAR DISORDER; CONTRAST SENSITIVITY; DRUG EFFECT; MIDDLE AGED; ORIENTATION; PATHOPHYSIOLOGY; PATTERN RECOGNITION; PERCEPTIVE DISCRIMINATION; PERCEPTIVE THRESHOLD; PERSONALITY TEST; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; RECURRENT DISEASE; REFERENCE VALUE; SYNAPTIC TRANSMISSION;

ADULT; ATTENTION; BIPOLAR DISORDER; CONTRAST SENSITIVITY; DEPRESSIVE DISORDER, MAJOR; DISCRIMINATION (PSYCHOLOGY); DOPAMINE; FEMALE; HUMANS; MALE; MIDDLE AGED; ORIENTATION; PATTERN RECOGNITION, VISUAL; PERSONALITY INVENTORY; REACTION TIME; RECURRENCE; REFERENCE VALUES; SENSORY THRESHOLDS; SYNAPTIC TRANSMISSION; YOUNG ADULT;

EID: 77449153489     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.1080/15622970701513756     Document Type: Article

References (44)

1. Ainsworth K, Smith SE, Sharp T. 1998. Repeated administration of fluoxetine desipramine and tranylcypromine increases dopamine D2-like but not D1-like receptor function in the rat. J Psychopharmacol 12:252-257.
2. Bodis-Wollner I. 1990. Visual deficits related to dopamine deficiency in experimental animals and Parkinson's disease patients. [Review, 68 refs.] Trends Neurosci 13:296-302.
3. Bodis-Wollner I. 1997. Vision and neurodegenerative diseases. Vision Res 37:3441-3443.
4. Bodis-Wollner I, Marx MS, Mitra S, Bobak P, Mylin L, Yahr M. 1987. Visual dysfunction in Parkinson's disease. Loss in spatiotemporal contrast sensitivity. Brain 110:1675-1698.
5. Brandstadter D, Oertel WH. 2003. Depression in Parkinson's disease. Review. Adv Neurol 91:371-381.
6. Chen Y, Levy DL, Sheremata S, Nakayama K, Matthysse S, Holzman PS. 2003. Effects of typical atypical and no antipsychotic drugs on visual contrast detection in schizophrenia. Am J Psychiatry 160:1795-1801.
7. Delgado PL. 2000. Depression: the case for a monoamine deficiency. [Review.] J Clin Psychiatry 61(Suppl 6):7\11.
8. Di Matteo V, Di Mascio M, Di Giovanni G, Esposito E. 2000. Acute administration of amitriptyline and mianserin increases dopamine release in the rat nucleus accumbens: possible involvement of serotonin2C receptors. Psychopharmacology 150:45-51.
9. Ebert D, Berger M. 1998. Neurobiological similarities in antidepressant sleep deprivation and psychostimulant use: a psychostimulant theory of antidepressant sleep deprivation. [Review]. Psychopharmacology 140:1-10.
10. Ebert D, Lammers CH. 1997. The central dopaminergic system and depression. [Review; German.] Nervenarzt 68:545-555.
11. Foley JM, Legge GE. 1981. Contrast detection and near-threshold discrimination in human vision. Vision Res 21:1041-1053.
12. Frederick JM, Rayborn ME, Laties AM, Lam DM, Hollyfield JG. 1982. Dopaminergic neurons in the human retina. J Comparative Neurol 210:65-79.
13. Friberg TR, Borrero G. 2000. Diminished perception of ambient light: a symptom of clinical depression? J Affect Disord 61:113-118.
14. Ghilardi MF, Marx MS, Bodis-Wollner I, Camras CB, Glover AA. 1989. The effect of intraocular 6-hydroxydopamine on retinal processing of primates. Ann Neurol 25:357-364.
15. Green DM, Swets JA. 1966. Signal detection theory and psychophysics. New York: Wiley.
16. Greenlee MW, Magnussen S. 1998. Limited-capacity mechanisms of visual discrimination. Vision Res 38:375-385.
17. Lambert G, Johansson M, Agren H, Friberg P. 2000. Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: evidence in support of the catecholamine hypothesis of mood disorders. Arch Gen Psychiatry 57:787-793.
18. Lammers CH, Diaz J, Schwartz JC, Sokoloff P. 2000. Selective increase of dopamine D3 receptor gene expression as a common effect of chronic antidepressant treatments. Mol Psychiatry 5:378-388.
19. Langheinrich T, Tebartz van Elst L, et al. 2000. Visual contrast response functions in Parkinson's disease: evidence from electroretinograms visually evoked potentials and psychophysics. Clin Neurophysiol 111:66-74.
20. Larisch R, Klimke A, Vosberg H, Loffler S, Gaebel W, Muller-Gartner HW 1997. In vivo evidence for the involvement of dopamine-D2 receptors in striatum and anterior cingulate gyrus in major depression. NeuroImage 5:251-260.
21. Lee B, Harris J. 1996. Contrast transfer characteristics of visual short-term memory. Vision Res 36:2159-2166.
22. Leinhaas MA, Hedstrom NJ. 1994. Low vision: how to assess and treat its emotional impact. Geriatrics 49:53-56.
23. Lemke MR. 1999. Motor signs of depression. [Review, German.] Nervenarzt 70:600-612.
24. Lieb K, Brucker S, Bach M, Els T, Lucking CH, Greenlee MW. 1999. Impairment in preattentive visual processing in patients with Parkinson's disease. Brain 122:303-313.
25. Liebermann HR, Pentland AP. 2003. Microcomputerbased estimation of psychophysical thresholds: The Best-Pest. Behav Res Methods Instrum 14:21-25.
26. Magnussen S, Greenlee MW. 1999. The psychophysics of perceptual memory. Psychol Res 62:81-92.
27. Mai J. 1990. Behavioral effects of antidepressant drugs given repeatedly on the dopaminergic system. Dopamine and mental depression. Oxford: Serra Pergamon. p 139-146.
28. Masson G, Mestre D, Blin O. 1993. Dopaminergic modulation of visual sensitivity in man. [Review.] Fundam Clin Pharmacol 7:449-463.
29. Mestre D, Blin O, Serratrice G, Pailhous J. 1990. Spatiotemporal contrast sensitivity differs in normal aging and Parkinson's disease. Neurology 40:1710-1714.
30. Northoff G, Demisch L, Wenke J, Pflug B. 1996. Plasma homovanillic acid concentrations in catatonia. Biol Psychiatry 39:436-443.
31. Palmer J. 1990. Attentional limits on the perception and memory of visual information. J Exp Psychol: Hum Percept Perform 16:332-350.
32. Praag HM, Korf J, Lakke JPWF, Schut T 1975. Dopamine metabolism in depressions psychoses and Parkinson's disease: the problem of the specificity of biological variables in behaviour disorders. Psychol Med 5:138-146.
33. Randrup A, Munkvad I, Fog R. 1975. Current developments in psychopharmacology. New York. p 207-229.
34. Ravnkilde B, Videbech P, Clemmensen K, Egander A, Rasmussen NA, Rosenberg R. 2002. Cognitive deficits in major depression. Scand J Psychol 43:239-251.
35. Scheibel AB. 1997. The thalamus and neuropsychiatric illness. J Neuropsychiatry Clin Neurosci 9:342-353.
36. Tebartz van Elst L, Greenlee MW, Foley JM, Lucking CH. 1997. Contrast detection discrimination and adaptation in patients with Parkinson's disease and multiple system atrophy. Brain 120:2219-2228.
37. Treutwein B. 1995. Adaptive psychophysical procedures. Vision Res 35(17):2503-2522.
38. Ventura R, Cabib S, Puglisi-Allegra S. 2002. Genetic susceptibility of mesocortical dopamine to stress determines liability to inhibition of mesoaccumbens dopamine and to behavioral 'despair' in a mouse model of depression. Neuroscience 115:999-1007.
39. Wells BG, Marken PA. 1989. Bromocriptine in treatment of depression. DICP: The Annals of Pharmacotherapy 23:600-602.
40. Wickens TD. 2001. Elementary signal detection theory. Oxford: Oxford University Press.
41. Willner P. 1983. Dopamine and depression: a review of recent evidence. I III. [Review, 162 refs.] Brain Res 287:211-246.
42. Willner P. 1995 Dopaminergic mechanisms in depression and mania. In: Bloom K, New York: Raven Press. p 921-932.
43. Yamamoto M. 2001. Depression in Parkinson's disease: its prevalence diagnosis and neurochemical background. [Review.] J Neurol 248(Suppl 3):I5-11.
44. Zhou FM, Liang Y, Salas R, Zhang L, De Biasi M, Dani JA. 2005. Corelease of dopamine and serotonin from striatal dopamine terminals. Neuron 46:65-74.